Ivabradin Hcs

Ivabradine, the active ingredient in Ivabradin Hcs, is a If (funny) channel inhibitor presented as a tablet for oral use. It treats chronic stable angina pectoris and heart failure with reduced ejection fraction in appropriate patients.

GNH USA supplies Ivabradin Hcs as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradin Hcs is indicated for conditions where reduction of heart rate improves clinical outcomes.

- Chronic stable angina pectoris: reduces the frequency of angina attacks by lowering heart rate. - Heart failure with reduced ejection fraction (NYHA class II–III): improves exercise capacity and lowers the risk of hospitalization through heart‑rate reduction.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Visual disturbances (phosphenes) - Headache - Dizziness - Fatigue

Serious or Rare Side Effects: - Severe bradycardia - Atrial fibrillation - Symptomatic hypotension

Use ivabradine with careful clinical monitoring.

- Heart rate monitoring: assess baseline and periodic heart rate to avoid excessive bradycardia. - Concomitant beta‑blockers: avoid combined use unless clinically justified. - Severe hepatic impairment: use with caution or avoid. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Ivabradine may interact with several medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine plasma concentrations. - Other heart‑rate‑lowering agents (e.g., beta‑blockers, digoxin): risk of severe bradycardia.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment. - CYP3A4 inducers (e.g., rifampicin): may reduce ivabradine efficacy. - Certain anti‑arrhythmic drugs (e.g., amiodarone): monitor heart‑rate response.